Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration.

• Publication year

  2017

• Venue

  Respiratory Medicine Case Reports

• Publication date

  2017-10-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rmcr.2017.10.006PMID 29124007PMCID 5671388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention and Treatment for Chemotherapy-Induced Peripheral 
Neuropathy: Therapies Based on CIPN Mechanisms

  2019cited by this paper
• (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1

  2017cited by this paper
• Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

  2017cited by this paper
• “Liquid elbows” due to afatinib administration

  2017cited by this paper
• Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma

  2017cited by this paper
• Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

  2017cited by this paper
• Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

  2017cited by this paper
• Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case series

  2017cited by this paper
• Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment

  2017cited by this paper
• Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

  2017cited by this paper
• PD-1 checkpoint inhibition: Toxicities and management.

  2017cited by this paper
• Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients. Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.

  2017cited by this paper
• The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer

  2017cited by this paper
• Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases

  2017cited by this paper
• Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

  2017cited by this paper
• Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations

  2017cited by this paper
• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

  2016cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

  2015cited by this paper
• Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

  2013cited by this paper
• Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy.

  2013cited by this paper
• Treatment of non-small cell lung cancer (NSCLC).

  2013cited by this paper

• FOXA1 Targets NEK2 to Mediate Cisplatin Resistance in Lung Adenocarcinoma Cells by Activating DNA Damage Repair

  2025cites this paper
• Immunotherapy for the elderly. Maybe the best option for lung cancer?

  2023cites this paper
• Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response

  2023cites this paper
• Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data

  2023cites this paper
• Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance

  2022cites this paper
• Lung cancer, treatment and nutritional status.

  2021cites this paper
• Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

  2021cites this paper
• Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report

  2020cites this paper
• Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

  2020cites this paper
• CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events.

  2020cites this paper
• Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors

  2020cites this paper
• Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer

  2020cites this paper
• Targeting the PD-1/PD-L1 Axis in Human Vitiligo

  2020cites this paper
• Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies.

  2019cites this paper
• Inhaled chemotherapy adverse effects: mechanisms and protection methods

  2019cites this paper
• Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods

  2019cites this paper
• Melanoma and Vitiligo: In Good Company

  2019cites this paper
• Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

  2019cites this paper
• Inhaled Cisplatin for NSCLC: Facts and Results

  2019cites this paper
• Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients

  2019cites this paper